The human pharmacology of reboxetine

Human Psychopharmacology

Volumn 13, Issue SUPPL. 1, 1998, Pages

  Szabadi, E ^a   Bradshaw, C M ^a   Boston, P F ^a,b   Langley, R W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Antidepressants; Autonomic functions; Desipramine; Noradrenaline reuptake; Reboxetine

Indexed keywords

DESIPRAMINE; REBOXETINE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; HORMONE RECEPTOR INTERACTION; HUMAN; MALE; NEUROTRANSMITTER UPTAKE; NORADRENALIN RELEASE; NORMAL HUMAN; PRIORITY JOURNAL; PUPIL REFLEX; SALIVATION;

EID: 0031951989     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199802)13:1+3.0.CO;2-O     Document Type: Conference Paper

References (20)

1. Alexanderson, B. (1972). Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and multiple oral doses. European Journal of Clinical Pharmacology, 4, 196-200.
2. Artigas, F. (1995). Selective serotonin/noradrenaline reuptake inhibitors (SNRIs): pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs, 4, 79-89.
3. Berzewski, H., Van Moffaert, M. and Gagiano, C. A. (1997). Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. European Neuropsychopharmacology, 7 (Suppl. 1), S37-S47.
4. Brunello, N. (1997). Rationale for the development of noradrenaline reuptake inhibitors (NARIs). Human Psychopharmacology, 13, S13-S19.
5. Clubley, M., Bye, C. E., Henson, T., Peck, A. W. and Riddington, C. (1978). A technique for studying effects of drugs on human sweat gland activity. European Journal of Clinical Pharmacology, 16, 221-226.
6. Dollery, C. (1991). Therapeutic Drugs. Churchill Livingstone, Edinburgh.
7. Edwards, D. M. F., Pellizzoni, C., Breuel, H. P., Berardi, A., Castelli, M. G., Frigerio, E., Poggesi, I., Rocchetti, M., Dubini, A. and Strolin Benedetti, M. (1995). Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharmaceutics and Drug Disposition, 16, 443-460.
8. Hyttel, J. (1994). Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology, 9 (Suppl. 1), 19-26.
9. Levitt, P. and Moore, R. Y. (1979). Origin and organization of brainstem catecholamine innervation in the rat. Journal of Comparative Neurology, 186, 505-528.
10. Maple, S., Bradshaw, C. M. and Szabadi, E. (1982). Pharmacological responsiveness of sweat glands in anxious patients and healthy volunteers. British Journal of Psychiatry, 141, 154-161.
11. Peck, R. E. (1959). The SHP test: an aid in the detection and measurement of depression. Archives of General Psychiatry, 1, 35-40.
12. Richelson, E. and Nelson, A. (1984). Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. Journal of Pharmacology and Experimental Therapeutics, 230, 94-102.
13. Riva, M., Brunello, N., Rovescalli, A. C., Galimberti, R., Carfagna, N., Carminati, P., Pozzi, O., Ricciardi, S., Roncucci, R., Rossi, A. and Racagni, G. (1989). Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. Journal of Drug Development, 1, 243-253.
14. Roose, S. P., Glassman, A. H., Attia, E. and Woodring, S. (1994). Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry, 151, 1735-1739.
15. Szabadi, E. and Bradshaw, C. M. (1986). Antidepressant drugs and the autonomic nervous system. In The Biology of Depression, Deakin, J. F. W. (ed.), Royal College of Psychiatrists/Gaskell, London, pp. 190-220.
16. Szabadi, E. and Bradshaw, C. M. (1988). Biological markers for anxiety states. In Recent Advances in Clinical Psychiatry, Granville-Grossman, K. (ed.), Volume 6, Churchill Livingstone, Edinburgh, pp. 69-99.
17. Szabadi, E. and Bradshaw, C. M. (1995). Affective disorders: 1. Antidepressants. In Seminars in Clinical Psychopharmacology, King, D. J. (ed.), Royal College of Psychiatrists/Gaskell, London, pp. 138-192.
18. 2-adrenoceptors. Journal of Psychopharmacology, 10 (Suppl. 3), 6-18.
19. Szabadi, E., Bradshaw, C. M. and Gaszner, P. (1980). The peripheral anticholinergic activity of tricyclic antidepressants: comparison of amitryptiline and desipramine in human volunteers. British Journal of Psychiatry, 137, 433-439.
20. Theofilopoulos, N., McDade, G., Szabadi, E. and Bradshaw, C. M. (1995). Effects of reboxetine and desipramine on the kinetics of the pupillary light reflex. British Journal of Clinical Pharmacology, 39, 251-255.